Recombinant Human HLA-A*24:02&B2M Monomer Protein (HEK293)，Avi & His

The study of the HLA-A*24:02 and beta-2 microglobulin (B2M) monomeric recombinant protein is crucial for understanding immune responses in the context of various diseases, particularly in the field of immunotherapy and vaccine development. HLA-A*24:02 is one of the most prevalent human leukocyte antigens in certain Asian populations and plays a significant role in presenting peptides to CD8+ T cells, thus influencing the body's immune response to tumors and viral infections. The beta-2 microglobulin is an essential component of the major histocompatibility complex (MHC) class I molecule, contributing to its stability and function. Research involving the recombinant expression of HLA-A*24:02 in combination with B2M facilitates the study of this complex's structure and function, enabling the elucidation of its interactions with specific peptides and T cell receptors. Understanding these molecular dynamics is pertinent for identifying potential therapeutic targets and designing personalized medicine approaches for patients with HLA-A*24:02, as it may help in developing effective cancer vaccines or immunotherapies. Furthermore, the production of monomeric forms of HLA-A*24:02 and B2M allows for in-depth biochemical analyses and high-resolution structural studies, which are essential for advancing our knowledge of immune evasion mechanisms employed by pathogens and tumors. Thus, the exploration of HLA-A*24:02 and B2M monomer recombinant proteins represents a significant avenue for immunological research, with potential implications for enhancing clinical outcomes in various diseases linked to immune dysfunction.